Anthracyclines in the treatment of patients with early breast cancer

Guarneri, Valentina; Azambuja, Evandro de

doi:10.1016/j.esmoop.2022.100461

Cited by 7 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study sample was mainly composed of breast cancer patients (93%), and the average cumulative anthracycline dose for the breast cancer patients in our study was roughly half of the average cumulative anthracycline dose for lymphoma cancer patients in our study. Additionally, breast cancer is typically treated with lower cumulative anthracycline dose than lymphoma cancer [ 14 ]. Prior studies included a smaller ratio of breast cancer patients, which indicates that chemotherapy dose may play a role in the relationship between adipose tissue depots and cardiotoxicity [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer

Mabudian,

Reding,

D’Agostino

et al. 2024

Cardio-Oncology

View full text Add to dashboard Cite

Background To understand how body composition in those with elevated body mass index impacts left ventricular function decline during cancer treatment, we determined the association between baseline body mass index (BMI), intra-abdominal adipose tissue (IAT) and subcutaneous adipose tissue (SAT) with baseline to 3-month left ventricular ejection fraction (LVEF) change among women receiving potentially cardiotoxic chemotherapy for breast cancer, lymphoma, or sarcoma. Methods Women underwent potentially cardiotoxic chemotherapy, such as doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab, for treatment of breast cancer, lymphoma, or sarcoma. We obtained magnetic resonance images (MRIs) of body composition and cardiac function prior to treatment, and then a repeat MRI for cardiac function assessment at three months into treatment. Analyses and assessment of abdominal adipose tissue volumes and LVEF outcomes were conducted by independent reviewers blinded to all patient identifiers. A general linear model was created to examine associations between adipose tissue depots, BMI, and 3-month LVEF change. Results Women (n = 210) aged 56 ± 11 years with breast cancer, lymphoma, and sarcoma were enrolled (n = 195, 14, 1 respectively). Baseline BMI, IAT, and SAT fat were independently associated with 3-month LVEF declines (p = 0.001 to 0.025 for all). After adjusting for baseline cardiovascular disease risk factors, BMI, IAT, and SAT, BMI remained the only variable associated with 3-month LVEF decline (p = 0.047). Conclusions These results suggest that factors other than abdominal adipose tissue or traditional cardiovascular risk factors may contribute to 3-month declines in LVEF among women with elevated BMI receiving potentially cardiotoxic chemotherapy. Further investigation should be conducted on psychosocial stress, physical activity, sleep, or diet. Trial registration DETECTIV_NCT01719562, WF99112, & WF97415—NCT02791581.

show abstract

Section: Discussionmentioning

confidence: 99%

The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer

Mabudian,

Reding,

D’Agostino

et al. 2024

Cardio-Oncology

View full text Add to dashboard Cite

show abstract

“…In TNBC, the indication for combination therapy is based on the KEYNOTE-522 trial, 43 where patients were selected using disease stage (computed tomography scan >2 cm or node-positive disease), and this should not change based on the latest update. 44 PD-L1 expression is key for selecting patients for immunotherapy in the metastatic setting; however, PD-L1 expression is not predictive of achieving pCR with immunotherapy.…”

Section: Patient Selection For Immunotherapy In Early Breast Cancermentioning

confidence: 99%

“…In early-stage ER+, HER2-breast cancer, KEYNOTE-756 (NCT03725059) showed a pCR benefit for immunotherapy in patients with tumors receiving pembrolizumab plus chemotherapy versus placebo (24.3% vs 15.6%) 44 ; longterm EFS follow-up data will add more clarity to the benefit of pembrolizumab in this setting. Interestingly, patients with ER-low tumors (1−10% expression) had a significantly higher probability of achieving pCR with pembrolizumab when compared to those with tumors with ER >10%.…”

Section: Patient Selection For Immunotherapy In Early Breast Cancermentioning

confidence: 99%

Recent Progress in Breast Cancer Treatment

2024

healthbook TIMES Onco Hema

View full text Add to dashboard Cite

Breast cancer remains a significant global health concern and the leading cancer type amongst women worldwide. While significant progress has been made in the field of breast cancer therapy, there are still many unmet goals that require attention and innovation. Current breast cancer research aims to develop more precise and effective tailored treatments to improve cure rates in patients with early disease and prolong survival among patients with metastatic disease while maintaining quality of life and minimizing treatment-related side effects. Additionally, there is a growing need to optimize patient selection criteria and provide comprehensive patient education during therapy. The European Society for Medical Oncology (ESMO) Congress 2023, held in Madrid, Spain, from October 20 to 24, featured several important clinical trials evaluating novel therapeutic strategies for various subtypes of breast cancer. This review article summarizes the data from selected studies presented at the ESMO 2023 Congress, along with the valuable perspectives shared by key opinion leaders in the field of breast cancer during the ESMO 2023 Breaking Science in Breast Cancer Video Series.

show abstract

“…Studies are ongoing to test if changes in miRNA expression can be used to indicate drug failure in eBC patients (NCT04771871). Defining patients with multi-drug resistance or potential toxicities to anthracyclines would contribute to identifying the best treatment choice and supporting chemotherapy de-escalation, enabling clinicians to safely withhold anthracyclines [182].…”

Section: Non-coding Rnas: Mirna and Circrnamentioning

confidence: 99%

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer

Gianni

Palleschi

Merloni

et al. 2022

Cancers

View full text Add to dashboard Cite

The research on non-invasive circulating biomarkers to guide clinical decision is in wide expansion, including the earliest disease settings. Several new intensification/de-intensification strategies are approaching clinical practice, personalizing the treatment for each patient. Moreover, liquid biopsy is revealing its potential with multiple techniques and studies available on circulating biomarkers in the preoperative phase. Inflammatory circulating cells, circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and other biological biomarkers are improving the armamentarium for treatment selection. Defining the escalation and de-escalation of treatments is a mainstay of personalized medicine in early breast cancer. In this review, we delineate the studies investigating the possible application of these non-invasive tools to give a more enlightened approach to escalating/de-escalating strategies in early breast cancer.

show abstract

Anthracyclines in the treatment of patients with early breast cancer

Cited by 7 publications

References 52 publications

The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer

The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer

Recent Progress in Breast Cancer Treatment

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer

Contact Info

Product

Resources

About